Morgan Stanley lowered the firm’s price target on Mondelez (MDLZ) to $71 from $73 and keeps an Overweight rating on the shares. The firm, which is lowering estimates to reflect recent scanner data trends in the U.S. and Western Europe and company commentary, now forecasts FY25 organic sales growth of 4.2%, down from 5.4% projected previously.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLZ:
- Mondelez International: Strategic Adjustments and Cost Reductions Support Buy Rating Amid Short-Term Challenges
- Berkshire to acquire OxyChem, OpenAI reaches $500B valuation: Morning Buzz
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Mondelez downgraded to Hold from Buy at Berenberg
- Mondelez praised by RFK Jr. for switching to natural food dyes